Results 11 to 20 of about 10,477 (203)

Update on the use of etanercept across a spectrum of rheumatoid disorders

Biologics: Targets & Therapy, 2008
Bernard CombeService d’Immuno-Rhumatologie, Montpellier, FranceAbstract: Etanercept is a soluble TNF receptor p75 fusion protein which is approved for subcutaneous use (50 mg weekly) in the treatment of patients with active rheumatoid arthritis
Bernard Combe
doaj   +1 more source

Evaluation of Efficacy and Safety of Etanercept and Etanercept + Methotrexate Therapy in Patients with Juvenile Idiopathic Arthritis without Systemic Manifestations

Вопросы современной педиатрии, 2016
Background: At present, it is urgent to find ways to overcome the inefficiency of and intolerance to the methotrexate therapy in patients with juvenile idiopathic arthritis (JIA).
T. M. Bzarova, Ye. I. Alekseeva, S. I. Valieva, R. V. Denisova, K. B. Isaeva, Ye. G. Chistyakova, A. M. Chomakhidze, T. V. Sleptsova, A. N. Fetisova, O. L. Lomakina, M. A. Soloshenko   +10 more
doaj   +2 more sources

Long-term safety and efficacy of etanercept in the treatment of ankylosing spondylitis

Patient Preference and Adherence, 2013
José Miguel Senabre-Gallego,1 Carlos Santos-Ramirez,2 Gregorio Santos-Soler,1 Esteban Salas-Heredia,1 Mabel Sánchez-Barrioluengo,3 Xavier Barber,4 José Rosas1 On behalf of the AIRE-MB group 1Rheumatology, Hospital Marina Baixa ...
Senabre-Gallego JM, Santos-Ramírez C, Santos-Soler G, Salas-Heredia E, Sánchez-Barrioluengo M, Barber X, Rosas J   +6 more
doaj   +1 more source

Etanercept, improved dosage schedules and combinations in the treatment of psoriasis: an update

Journal of Inflammation Research, 2009
Siegfried SegaertDepartment of Dermatology, University Hospital Leuven, BelgiumAbstract: Etanercept, a subcutaneously administered fully human soluble tumor necrosis factor (TNF) receptor, was initially approved for the treatment of psoriasis at a dose ...
Siegfried Segaert
doaj   +1 more source

Etanercept (Enbrel®) alternative storage at ambient temperature

Clinical Pharmacology: Advances and Applications, 2017
Edel Shannon,1 Joanne Daffy,2 Heather Jones,3 Andrea Paulson,4 Steven M Vicik5 1Global Chemistry, Manufacturing, and Controls Regulatory, 2Contract Operations Quality Assurance, Pfizer Ireland Pharmaceuticals, Clondalkin, Dublin, Ireland; 3Medical ...
Shannon E, Daffy J, Jones H, Paulson A, Vicik SM   +4 more
doaj   +1 more source

Patient-reported outcomes data in patients with psoriatic arthritis from a randomised trial of etanercept and methotrexate as monotherapy or in combination

RMD Open, 2021
Objectives We examined patient-reported outcomes (PROs) in The Study of Etanercept And Methotrexate in Patients with Psoriatic Arthritis (PsA); a 48-week, phase 3, randomised controlled trial that compared outcomes with methotrexate (MTX) monotherapy ...
Vibeke Strand, Ervant J Maksabedian Hernandez, Bradley S Stolshek, Lyrica X H Liu, David H Collier, Gregory Kricorian   +5 more
doaj   +1 more source

Etanercept Ameliorates Cardiac Fibrosis in Rats with Diet-Induced Obesity

Pharmaceuticals, 2021
Diet-induced obesity (DIO) is considered the main risk factor for cardiovascular diseases. Increases in the plasma levels of tumor necrosis factor alpha (TNF-α) is associated with DIO.
Chia-Chen Hsu, Yingxiao Li, Chao-Tien Hsu, Juei-Tang Cheng, Mang-Hung Lin, Kai-Chun Cheng, Shang-Wen Chen   +6 more
doaj   +1 more source

Adherence to etanercept therapy in rheumatoid arthritis patients during 3 years of follow-up. [PDF]

PLoS ONE, 2018
OBJECTIVES:To determine the percentage non-adherence to etanercept in patients with rheumatoid arthritis during three years of follow-up. METHODS:During study visits in this prospective cohort study, blood samples were taken to determine serum etanercept
E H Vogelzang, R C F Hebing, M T Nurmohamed, A W R van Kuijk, J W F Kruijff, M J l'Ami, C L M Krieckaert, G Wolbink   +7 more
doaj   +1 more source

Etanercept biosimilars [PDF]

Rheumatology International, 2014
Etanercept was the first tumour necrosis factor alpha antagonist approved in the USA for the treatment of rheumatoid arthritis, in 1998, and then for other diseases. With the etanercept patent set to expire in the EU in 2015, a number of etanercept copies have reached the production phase and are undergoing clinical trials, with the promise of being ...
Azevedo, Valderilio F., Galli, Nathalia, Kleinfelder, Alais, D’Ippolito, Julia, Urbano, Paulo C. M.   +4 more
openaire   +2 more sources

Effect of etanercept on post-traumatic proliferative vitreoretinopathy [PDF]

International Journal of Ophthalmology, 2019
AIM: To evaluate the safety and efficacy of intravitreal etanercept in the inhibiting of proliferative vitreoretinopathy (PVR) in a model of penetrating ocular injury.
Xiao-Feng Chen, Mei Du, Xiao-Hong Wang, Hua Yan   +3 more
doaj   +1 more source